While this therapeutic plan is required for the survival of T1D individuals, the limitations of exogenous insulin therapy include the frequent occurrence of glycemic excursions and recurrent episodes of hypoglycemia, situations that, in due course, will contribute to the development and/or exacerbation of debilitating secondary complications, some of which are life-threatening [4]. This evidence concerns the gene INS and type 1 diabetes mellitus.